[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495214":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":13,"centralContacts":13,"locations":31,"responsibleParty":51,"collaborators":55,"id":60,"slug":13,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":13,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":13,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":13,"overallStatus":33,"whyStopped":13,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Shantou Central Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"RCB","Residual Cancer Burden","7 days",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":13,"interventionNames":24},"dose-dense arm","EXPERIMENTAL",[25],"Drug: dose-dense nab-paclitaxel followed by EC",[27],{"type":28,"name":29,"description":29,"armGroupLabels":30,"otherNames":13},"DRUG","dose-dense nab-paclitaxel followed by EC",[22],[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Shantou","Guangdong","510000","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.67876,23.35489,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":49,"phoneExt":13,"email":50},"Haitong Lyu","CONTACT","+8613631403739","heton25@foxmali.com",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Zhiyong Wu","Dr.",[56,58],{"name":57,"class":6},"Shantou University Medical College",{"name":59,"class":6},"Jieyang People's Hospital","100495214",false,"NCT05728268","Neoadjuvant Dose-dense Chemotherapy for HR+\u002FHER2- Breast Cancer Patients With High Proliferation Index","Inclusion Criteria:\n\n* Females with age of 18 to 70 years old.\n* Newly diagnosed breast cancer patients.\n* Planned neoadjuvant chemotherapy.\n* Hormone receptor status: Estrogen receptor (ER)-positive or Progesterone Receptor (PR)- positive.\n* HER2\u002Fneu-negative.\n* Ki67≥30%.\n* Clinical stage IIB-IIIC.\n* Informed consent form understood and signed.\n* Patient agrees to all follow-up visits.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n* Women of childbearing potential must have a negative serum pregnancy test.\n\nExclusion Criteria:\n\n* Metastatic disease\n* Pregnancy.\n* Nursing mothers.\n* Active or uncontrolled infection.\n* Presence of another malignancies.\n* Granulocyte count \\\u003C 1.5\\*10\\^9\u002FL.\n* Platelet count \\\u003C 100\\*10\\^9\u002FL.\n* Hemoglobin \\\u003C 90g\u002FL.\n* Serum Creatinine more than 1.5 upper limit.\n* AST and ALT more than 2.5 upper limit.\n* LVEF\\\u003C 50%.","FEMALE","18 Years","70 Years",{"count":69,"type":70},64,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","Studies have shown that dose-dense chemotherapy reduces the risk of recurrence and death of breast cancer patients comparing with standard-schedule chemotherapy. But some research data indicate that HR+\u002FHER2- breast cancer patients benefit from dose-dense chemotherapy while some have negative results. How to identify HR+\u002FHER2 breast cancer patients who are more likely to benefit from dose-dense chemotherapy is strongly necessary. Ki67 is a marker reflecting the proliferation of tumor cells. Breast cancer patients with high Ki67 are more likely to benefit from dose-dense chemotherapy. The purpose of this project is to investigate the efficacy and safety of neoadjuvant dose-dense chemotherapy for HR+\u002FHER2- breast cancer patients with high proliferation index. At the same time, we will explore biomarkers, such as MammaPrint and BluePrint, to further identify patients who benefit more from neoadjuvant dose-dense chemotherapy.",[76],"Breast Cancer","2025-12-28",{"date":79,"type":80},"2026-01-02","ACTUAL",{"date":82,"type":80},"2021-08-01",{"date":84,"type":70},"2025-12-30",{"name":5,"class":6},1]